Navigation Links
Uptake of Branded Agents Will Drive the Systemic Lupus Erythematosus Drug Market to Quadruple to $1.4 Billion in 2016

Entry of Novel Therapies Including Rituxan/MabThera and Increased Uptake of CellCept Will Provide Effective Treatment Options, According to a New

Report from Decision Resources

WALTHAM, Mass., Feb. 25 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the entry and uptake of high-priced branded agents will drive the systemic lupus erythematosus drug market to quadruple from approximately $325 million in 2006 to $1.4 billion in 2016.

The new Pharmacor report entitled Systemic Lupus Erythematosus finds that the strongest drivers of market growth will be the formal approval of several therapies that target B cells, including Biogen Idec/Genentech/Zenyaku Kogyo's Rituxan/Roche's MabThera, as well as increased uptake of Roche/Aspreva Pharmaceuticals' branded immunosuppressant CellCept.

"The introduction of novel biologics, other targeted therapies, and immunosuppressants into the treatment regimens of patients with systemic lupus erythematosus will result in increased polypharmacy," said Amy Whiting, Ph.D., analyst at Decision Resources. "These agents will not replace existing therapies but rather be used in combination with existing drugs to provide more-effective and/or safer treatment."

The report finds that sales in the systemic lupus erythematosus drug market will experience a significant 24% annual increase between 2006 and 2011. Sales growth will then proceed at a slower pace of 9% annually from 2011 to 2016, owing to fewer new product launches, generic erosion of CellCept, and biogeneric erosion of Rituxan/MabThera.

About Systemic Lupus Erythematosus

Systemic lupus erythematosus is an autoimmune disease characterized by a complex pathophysiology that results in widespread tissue damage of multiple organ systems. The disease affects more than 537,000 people in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The diagnosed prevalence of systemic lupus erythematosus is approximately ten times higher in women than in men.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be

trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.


SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Varian and BrainLAB Announce Rapid Uptake of Powerful and Versatile Radiosurgery Platform
2. Novel 3-D cell culture model shows selective tumour uptake of nanoparticles
3. The Branded Pharmaceutical Association Comments on Hydrocodone
4. FTCR: Gov. Schwarzenegger Must Follow Through on Call to Ban Blue Cross From Using Doctors as Double-Agents to Dump Sick Patients
5. ABR-Affinity BioReagents Participates in the 2008 Fisher Scientific Supplier Expo in San Antonio, Texas
6. LiquidAgents Healthcare, LLC Awarded Accreditation from the Joint Commission
7. Insurance Agents Call for State Senate to Improve Californias Health Care Reform Compromise
8. Allergic reactions to gadolinium-based contrast agents are rare, study finds
9. Germ-Fighting Inhaler Could Fend Off Bioterror Agents
10. National Patient Advocate Foundation (NPAF) Statement Regarding New FDA Label on Erythropoietin Stimulating Agents (ESAs)
11. Benepath Launches Exclusive Marketing Service for Health Insurance Agents and Agencies
Post Your Comments:
(Date:11/30/2015)... , ... November 30, 2015 , ... According to Los ... people to overeat are not necessarily caused by real hunger, but instead by ... needs food. He notes that, while many patients are aware that weight loss surgery ...
(Date:11/30/2015)... ... November 30, 2015 , ... A record crowd gathered at the ... organized by the Baruch S. Blumberg Institute. , The institute, which is the research ... science and biotechnology leaders for the conference, which focused on ways companies can work ...
(Date:11/30/2015)... ... November 30, 2015 , ... A novel class of antimicrobials ... effective in fighting methicillin-resistant Staphylococcus aureus (MRSA), one of the major drug-resistant bacterial ... small molecule analogs that target the functions of SecA, a central part of ...
(Date:11/30/2015)... NJ (PRWEB) , ... November 30, 2015 , ... ... top choice for innovative, patient centered orthopedic care. Led by John Vitolo, ... your injury or chronic condition, the team at Advocare Orthopedic & Sports Medicine ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... specializes in general dentistry out of Glen Ridge, NJ. He has both ... to achieve optimal mastication. He is also an expert in cosmetic dentistry. ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 30, 2015 Diplomat Pharmacy, Inc. (NYSE: ... the Detroit Free Press as a Top Workplace , ... to work for in 2015. ... 100 winners annually, based on employee surveys rating company leadership, ... Workplaces are based solely on employee feedback. The survey is ...
(Date:11/30/2015)... , Nov. 30, 2015  IBA Molecular North America, ... distribution of radiopharmaceuticals, announced that as of January 1, ... (Zevacor Pharma). The decision to rebrand the company reflects ... as well as its close relationship with Zevacor Molecular.  ... Health and Science (IHS). Peter Burke ...
(Date:11/30/2015)... 30, 2015 Baxalta Incorporated (NYSE: ... dedicated to delivering transformative therapies to patients ... today announced the launch and first shipments ... extended circulating half-life recombinant factor VIII (rFVIII) ... ADVATE [Antihemophilic Factor (Recombinant)]. The treatment was ...
Breaking Medicine Technology: